Delivering the Added Dimension in Drug Discovery Services
Drug Metabolism and Pharmacokinetics (DMPK) is an integral part of drug discovery. Its central role is to contribute to the optimization of novel chemical entities in drug discovery by balancing the properties associated with drug gastrointestinal absorption (for orally delivered therapies), distribution, clearance, elimination and DDI potential as rapidly and cost-effectively as possible.
The DMPK department comprises in-vitro, in-vivo, metabolite ID and pre-formulation groups, managed by highly experienced and matured scientists. We guide discovery projects by troubleshooting scientific issues and offer changes on scaffolds to drive discovery projects in the right direction and de-risk failures in the later stage of development due to DMPK related issues.
Jubilant’s DMPK technical and research services meet the highest standards of professional performance to satisfy the unique requirements of our clients. Our team supports both integrated pre-clinical discovery programs and fixed-fees-for-services (FFS) projects and delivers quality and reproducible results with quick turnaround time. We work closely with our clients to identify their needs and clarify their expectations, including cost and time constraints.
The team provides in-vitro ADME services (absorption, distribution, metabolism and excretion) with the expertise to guide discovery projects from hit identification, through hit to lead optimization, and then lead optimization up to the identification of clinical candidates. To reduce the chance of failures in development, we troubleshoot and offer changes on scaffolds for a quick go/no-go decision at the discovery stage.
The team has a track record to carry various in-vitro studies or in-vitro ADME screening at various stages of the drug discovery and development process to flag potential issues such as:
The DMPK team has published several research articles in peer-reviewed international journals and presented posters in conferences.